Alira Health’s Transformation Talks: Early Access Programs: Why and How?

Published on:
January 19, 2022

Early Access Programs (EAPs) offer the healthcare industry enormous advantages – not only do they allow patients with a high unmet medical need access to the innovative medicines prior to their commercialization, but they also allow pharmaceutical companies to generate KOL engagement, enabling them to accelerate reimbursement while leveraging evidence to support P&R and market access.

However, despite all significant benefits, EAPs still remain a black box for the industry due to their complexity.

Listen to this episode of “Transformation Talks” to discover the benefits and challenges of implementing EAPs from both the industry and payer perspectives, and the main recommendations for their effective design and implementation in Europe.

This episode’s guests include Lois Beecroft, Global Pricing and Market Access Director at GSK, and Jacqui Lyttle, Senior Independent Director at NHS Foundation Trust in Torbay and South Devon, our host Kenny Carberry, Associate Director of Clinical Development at Alira Health, and our co-host Nerea Blanqué-Catalina, VP of Global Market Access & Pricing at Alira Health.  

Would you like to understand the complexity of launching EAPs, discover their benefits and learn about the related challenges and ways to overcome them?


Related news

Multimedia May 10, 2022
VacciTalks: Behind the Scenes: Challenging Race of Vaccine Development
Join the 2nd episode of VacciTalks where together with vaccine expert Roberto Camerini we will peek behind the scenes of vaccine development and get an insider look at the difficulties,(...)
Market Access
Events May 9, 2022
7e Journée start-up innovantes du dispositif médical
Clinical Digital Health Market Access MedTech Research & Development
Multimedia April 28, 2022
Alira Health’s Transformation Talks: Real-World Data to Support HTAs in Europe
Learn more about RWD as a support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.
Clinical Market Access RWE
Publications April 20, 2022
White Paper: Next Generation Therapies: Access, Pricing and Ethical Issues in Perspective
In this white paper, we will explore wide range of new therapies we term “Next Generation Therapies” and challenges related to them.
Market Access
Publications March 31, 2022
Real-World Evidence: Five Facts You Need to Know
Learn more about RWD and its future challenges for Europe, we asked Romain Finas, Vice President of Real-World Evidence (RWE) at Alira Health, to share five facts that you need to know about it.
Market Access RWE
Publications March 25, 2022
Early Access Programs: Keys to Success
Discover Alira Health’s top five recommendations to building a successful Early Access Programs (EAP). 
Market Access
News March 22, 2022
Alira Health and HTAi Collaborate to Develop a Multi-Stakeholder Value Assessment Framework for Robotic-Assisted Surgery & Digital Health
Learn more about the new evidence-based guidance on HTA for Robotic-Assisted Surgery and Digital Health Technologies. 
Market Access
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.